drugset / Trial / NCT07281014
Unmitigated Aldosterone Signaling During Standard Clinical MRA Dosing
RandomizedCrossoverQuadruple-blindBasic science
Summary
The purpose of this research study is to understand the biology related to the potential shortcomings of existing anti-aldosterone therapy.
Timeline
- Start
- 2026-01-27
- Primary completion
- 2027-08
- Completion
- 2027-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aldosterone | Small molecule | — | Intravenous |
| Comparator | Spironolactone | Small molecule | 25 mg | Oral |